- Previous Close
89.12 - Open
89.02 - Bid 87.32 x 1100
- Ask 87.84 x 900
- Day's Range
87.65 - 89.24 - 52 Week Range
68.84 - 91.49 - Volume
3,434,764 - Avg. Volume
6,519,942 - Market Cap (intraday)
112.574B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
29.55 - EPS (TTM)
2.97 - Earnings Date Nov 19, 2024
- Forward Dividend & Yield 2.80 (3.14%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
94.75
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
www.medtronic.comRecent News: MDT
View MorePerformance Overview: MDT
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDT
View MoreValuation Measures
Market Cap
114.31B
Enterprise Value
134.33B
Trailing P/E
30.01
Forward P/E
16.34
PEG Ratio (5yr expected)
1.65
Price/Sales (ttm)
3.61
Price/Book (mrq)
2.38
Enterprise Value/Revenue
4.12
Enterprise Value/EBITDA
16.22
Financial Highlights
Profitability and Income Statement
Profit Margin
12.06%
Return on Assets (ttm)
4.41%
Return on Equity (ttm)
7.95%
Revenue (ttm)
32.58B
Net Income Avi to Common (ttm)
3.93B
Diluted EPS (ttm)
2.97
Balance Sheet and Cash Flow
Total Cash (mrq)
7.84B
Total Debt/Equity (mrq)
57.86%
Levered Free Cash Flow (ttm)
4.9B
Research Analysis: MDT
View MoreCompany Insights: MDT
MDT does not have Company Insights
Research Reports: MDT
View MoreLarge Cap US Pick List - September 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Positive upside on revenue growth in 1Q25
With operational headquarters in Minneapolis, Medtronic is one of the world's largest medical technology and solutions companies. Its devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments for diabetes and neurological conditions, vascular therapies, and cardiac surgery. MDT is a component of the S&P 500.
RatingPrice TargetAs of this writing, major indices are getting closer and closer to their
As of this writing, major indices are getting closer and closer to their all-time highs (ATHs) from July 10 and July 16 (S&P 500 and S&P 400, respectively). The only major index that has bounced enough to reclaim ATH territory is the NYSE Composite, probably due to the minor 5.6% pullback the index saw in the second half of July and early August. The S&P 500 (SPX) is within 1% of its July 16 all-time closing high of 5,667.20 and remains on its 'V' shaped formation and trajectory. The Chande Trend Meter is back up to 83%, indicating a strong and strengthening trend; the Vortex Indicator is close to bullish territory; the 14-day Relative Strength index is back above the midline 50% level; the daily MACD is back in positive territory; and the 21-day rate-of-change has cycled back into bullish territory after dropping into negative territory at the start of August. Some 75% of SPX stocks are above their key 200-day average, while 73% (up from 44% on August 5) are above their 50-day. More impressive, the more-concentrated S&P 100 (OEX) is showing 83% of its stocks above their 200-day average, up from a recent 65%. Both the SPX and OEX advance-decline (AD) lines have surged to ATHs prior to price; historically, that has been very bullish for at least the intermediate-term period. The Nasdaq 100 (QQQ) is 4.5% from its ATH near 503 and its AD line has posted an ATH prior to price. Some 71% of QQQ issues are above their 200-day, up from 44% just 10 days ago, while the percentage above the 50-day has jumped to 61% from 29% on August 7.
Medtronic Earnings: New Products Support a Strong Start to the New Fiscal Year
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
RatingPrice Target